PNT NASDAQ
POINT Biopharma Global Inc.
1W: +0.2%
1M: -8.4%
3M: +87.4%
1Y: +85.2%
3Y: -12.8%
$12.50
Last traded 2023-12-29 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
2 relationships0
As Filer
counterparties named
2
As Counterparty
mentioned by others
2022-11-14
Earliest Filing
2022-12-20
Latest Filing
Mentioned As Counterparty
2 mentionsOther companies that named PNT in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| LNTH Lantheus Holdings, Inc. | partner | Strategic collaboration to co-develop and commercialize PNT-2002 and PNT-2003 radiopharmaceutical therapies. | 2022-12-20 | View |
| LNTH Lantheus Holdings, Inc. | partner | Entered into license and collaboration agreements with Lantheus subsidiaries to co-develop and commercialize PNT-2002 an | 2022-11-14 | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR